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Introduction: Effective in vivo models of breast cancer are crucial for studying the development and progression of
the disease in humans. We sought to engineer a novel mouse model of polyomavirus middle T antigen (PyV mT)-
mediated mammary tumourigenesis in which inducible expression of this well-characterized viral oncoprotein is
coupled to Cre recombinase (TetO-PyV mT-IRES-Cre recombinase or MIC).
Methods: MIC mice were crossed to the mouse mammary tumour virus (MMTV)-reverse tetracycline transactivator
(rtTA) strain to generate cohorts of virgin females carrying one or both transgenes. Experimental (rtTA/MIC) and
control (rtTA or MIC) animals were administered 2 mg/mL doxycycline beginning as early as eight weeks of age
and monitored for mammary tumour formation, in parallel with un-induced controls of the same genotypes.
Results: Of the rtTA/MIC virgin females studied, 90% developed mammary tumour with complete penetrance to all
glands in response to doxycycline and a T50 of seven days post-induction, while induced or un-induced controls
remained tumour-free after one year of induction. Histological analyses of rtTA/MIC mammary glands and tumour
revealed that lesions followed the canonical stepwise progression of PyV mT tumourigenesis, from hyperplasia to
mammary intraepithelial neoplasia/adenoma, carcinoma, and invasive carcinoma that metastasizes to the lung; at
each of these stages expression of PyV mT and Cre recombinase transgenes was confirmed. Withdrawal of
doxycycline from rtTA/MIC mice with end-stage mammary tumours led to rapid regression, yet animals eventually
developed PyV mT-expressing and -non-expressing recurrent masses with varied tumour histopathologies.
Conclusions: We have successfully created a temporally regulated mouse model of PyV mT-mediated mammary
tumourigenesis that can be used to study Cre recombinase-mediated genetic changes simultaneously. While
maintaining all of the hallmark features of the well-established constitutive MMTV-PyV mT model, the utility of this
strain derives from the linking of PyV mT and Cre recombinase transgenes; mammary epithelial cells are thereby
forced to couple PyV mT expression with conditional ablation of a given gene. This transgenic mouse model will
be an important research tool for identifying synthetic viable genetic events that enable PyV mT tumours to evolve
in the absence of a key signaling pathway.* Correspondence: william.muller@mcgill.ca
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Since its discovery in the 1950s, studies on the polyoma-
virus middle T antigen (PyV mT) have been essential in
understanding cellular signalling and tumourigenesis.
PyV mT can readily transform cells in vitro and in vivo
by stimulating key pro-tumourigenic signalling axes.
Phosphorylation of the membrane-anchored PyV mT
protein by Src family tyrosine kinases leads to the re-
cruitment and activation of specific proto-oncogenes
such as Shc and phosphatidyl inositol 3’ kinase. In recent
decades, the signalling pathways initiated by these effec-
tors have been found to be activated in several human
tumours and, consequently, PyV mT model systems
continue to be employed in cancer research (reviewed
extensively in [1]).
Transgenic expression of PyV mT in the mouse can lead
to tumour formation in many epithelial tissues [2]. Per-
haps most valuable to the field of breast cancer is the
widely used mouse mammary tumour virus (MMTV)-
driven PyV mT mouse model, in which transgene expres-
sion occurs in the mammary epithelium [3]. Mammary
tumour development in this strain closely mimics the dis-
ease progression observed in humans, evolving through
four distinct stages: hyperplasia, mammary intraepithelial
neoplasia (MIN)/adenoma, early carcinoma and late car-
cinoma [4]. Another clinically relevant feature of this
model is that PyV mT-induced mammary tumours are
capable of metastasizing to the lungs [3]. First published
two decades ago, the MMTV-PyV mT strain has since be-
come an established tool in studying breast tumourigen-
esis and metastasis in vivo.
Initial attempts to study the mammary-specific role of
a particular gene in the MMTV-PyV mT model involved
crossing in LOXP-flanked alleles of this gene as well
as an MMTV-driven Cre recombinase transgene. How-
ever, the MMTV promoter is only active in approxi-
mately 70% of the mammary epithelium, resulting in
stochastic Cre recombinase expression in PyV mT tumour
tissue; a selection for PyV mT-positive/Cre recombinase-
negative cells arises in the developing tumour, preclud-
ing excision of the conditional allele of interest. This
phenomenon has occurred in several MMTV-PyV mT/
MMTV-Cre recombinase backgrounds as demonstrated
by our own laboratory: conditional ablation of β1-integrin,
focal adhesion kinase, c-Src or Stat3 was prevented, indi-
cating that in each case the conditional gene was most
likely essential to PyV mT-driven tumourigenesis [5-7]
(unpublished observations; Ranger JJ, Muller WJ). The
idea of coupling Cre recombinase expression to that of
the oncogene to circumvent this selection process was
successfully demonstrated in the MMTV-NIC (Neu-IRES-
Cre recombinase) model of ErbB2/Neu breast cancer, in
which a mutant Neu transgene is linked to Cre recombin-
ase through an internal ribosome entry sequence (IRES)[8]. Every mammary tumour cell expresses both Neu and
Cre recombinase and, thus, any conditional loci present in
the genome of this cell should be recombined and com-
pletely ablated.
In addition to replicating this coupling strategy for a
new PyV mT strain, we sought to expand the applicabil-
ity of the model to temporal regulation. The recent
departure from constitutive or hormone-responsive pro-
moters in transgenic breast cancer mouse models (for
example, MMTV) to a chemically-inducible approach
has been made possible by the advent of the MMTV-
reverse tetracycline transactivator (rtTA) strain used in
combination with the well-established TetON system
[9]. The tetracycline-inducible promoter is only turned
on in response to the tetracycline derivative, doxycycline,
in contrast to the hormone-responsive MMTV promoter
that becomes constitutively active at approximately three
weeks of age. By turning on expression of a tetracycline-
responsive transgene in the adult mouse, one can avoid
potential complications caused by overexpression of the
oncogene or by Cre recombinase-mediated removal of a
LOXP-flanked cassette during development; likewise, ex-
pression can then be turned off after tumour formation
to investigate the possibility of regression and recur-
rence. It should be noted that a TetON-PyV mT mouse
strain has been reported which is sensitive to inducible
mammary tumour progression in the presence of the
MMTV-rtTA transgene; however, PyV mT is not
coupled to Cre recombinase in this case [10].
In order to link expression of the PyV mT oncogene
with that of Cre recombinase in an inducible manner,
we generated a TetO-PyV mT-IRES-Cre recombinase
(MIC) transgenic mouse that, when crossed to the
MMTV-rtTA strain and treated with doxycycline, ex-
presses both PyV mT and Cre recombinase from the
same bi-cistronic transcript in the mammary epithelium.
In the majority of experimental mice, mammary tu-
mours develop within two weeks of induction, progress
through the typical PyV mT histological stages, and
metastasize to the lung. These tumours were susceptible
to regression upon doxycycline withdrawal; however, re-
current tumours ultimately arose in de-induced animals.
This research article details the characterization of this
novel inducible model and reflects on its potential use in
future studies of PyV mT mammary tumourigenesis.
Methods
Generation of the MIC construct and rtTA/MIC
bigenic strain
The MIC construct was created using the pTE-mElf5-
IRES-eGFP vector (a generous gift from Dr. C. Ormandy).
Briefly, after removal of the mElf5 and eGFP trans-
genes, PyV mT cDNA was sub-cloned between the Tet-
operator (TetO) and internal ribosome entry sequence
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cDNA downstream of the IRES (TetO-PyV mT-IRES-
Cre recombinase; abbreviated as MIC) (Additional file 1:
Figure S1). Derivation of the MIC strain was conducted
in the Transgenic Core Facility in the Goodman Cancer
Research Centre using standard pronuclear injection of
FVB/N single cell embryos [11]. Progeny were screened
for germ-line transmission of the MIC transgene by PCR
genotyping. MMTV-reverse tetracycline transactivator
(rtTA) transgenic mice were generated in the laboratory
of Dr. Lewis Chodosh as previously described [9]. The
ROSA26 Cre recombinase-activated β-galactosidase re-
porter strain (GTRosa) was generated in the laboratory
of Dr. Phillipe Soriano as previously described [12]. All
mice were housed in the animal facility at the Goodman
Cancer Research Centre. Ethical approval was obtained
for the use of animals and all experiments were done
in accordance with the animal care guidelines at the
Animal Resource Centre of McGill University. All trans-
genic animals described in this study were on a pure
FVB/N background.Doxycycline induction of rtTA/MIC mice and necropsy
procedures
Experimental and control animals of at least eight
weeks of age were given drinking water containing 2
mg/mL doxycycline (Sigma Aldrich, St. Louis, MO,
USA) in light-blocking bottles each week. Mammary
tumours were detected by physical palpation and an-
imals were sacrificed at a total tumour burden of six
cubic centimetres unless otherwise specified. Mater-
ial from necropsied mice was flash frozen in liquid
nitrogen (in some cases, tissues were set in an OCT
medium before freezing) or fixed in 10% neutral
buffered formalin (Leica Microsystems Inc., Concord,
ON, Canada) and embedded in paraffin wax. Fixed
and embedded mammary tissues were sectioned at 4
μm and either stained by haematoxylin and eosin
(H&E) or processed further as indicated. H&E-
stained lung sections (4 μm) were scanned with a
Scanscope XT Digital Slide Scanner and for each
sample the area occupied by metastases relative to
the total lung area was quantified using Imagescope
software (Aperio, Vista, CA, USA). The number and
type of lesions in mammary gland sections were
counted similarly by analysing 10 fields within a
scanned image of each sample. Inguinal mammary
glands were whole mounted on glass slides and
processed for H&E-staining as described [6]. For re-
section surgeries, mice were anesthetised prior to ex-
cising a small piece of tumour for embedding and
flash freezing; the incision was sutured and pain-
killers administered for one week.Immunoblotting
Flash frozen mammary tissues were lysed as in [6]
and 20 μg of protein were separated by SDS-PAGE.
Membranes were immunoblotted with the follo-
wing primary antibodies: E-cadherin (BD Biosciences,
Mississauga, ON, Canada; 610182, 1:1,000); Cre recom-
binase (Novagen/EMD Millipore, Billerica, MA, USA;
69050, 1:1,000); P-EGFR (Y1068) (Cell Signaling/New
England Biolabs, Pickering, ON, Canada; #3777, 1:1,000);
EGFR (Cell Signaling #2322, 1:1,000); P-ErbB2 (Y1248)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA;
#12352, 1:500); ErbB2 (Santa Cruz Biotechnology #284,
1:1,000); Hsp90 (Cell Signaling #4874); PyV mT (a gen-
erous gift from Dr. S. Dilworth, Ab750, 1:1000), c-Myc
(Santa Cruz Biotechnology #764); P-PDGFRβ (Y1021)
(Cell Signaling #2227, 1:1,000); PDGFRβ (Cell Signaling
#3175, 1:1,000); α-tubulin (Cell Signaling #2125). Horse
radish peroxidase (HRP)-conjugated secondary anti-
bodies were purchased from Jackson ImmunoResearch
Laboratories, West Grove, PA, USA. GE Amersham
(Bai d'Urfe, QC, Canada) enhanced chemilumine-
scence detection reagents were used to visualize the
immunoblots.
Immunohistochemistry
Sections of paraffin-embedded samples were immuno-
stained as described previously [6]. Antigen retrieval was
performed in 10 mM sodium citrate buffer. Sections
were blocked in a solution of Power Block Universal
Blocking Agent (Biogenex , Fremont, CA, USA) and in-
cubated with primary antibodies: PyV mT (a generous gift
from Dr. S. Dilworth, Ab762, 1:100) or Cre recombinase
(Covance, Denver, PA, USA; PRB 106C, 1:600). In the case
of PyV mT, the sections were incubated with anti-mouse s
econdary antibody conjugated to HRP (Dako, Burlington,
ON, Canada; #K4006). For Cre recombinase, the sections
were incubated first with biotinylated anti-rabbit second-
ary antibody (Jackson ImmunoResearch Laboratories) and
then with avidin conjugated to HRP (Vector Labs,
Burlington, ON, Canada; Vectastain Elite ABC kit #PK-
6100). Development was carried out by exposing with
DAB reagent (Dako #K3467). Slides were counterstained
with 20% haematoxylin before mounting.
β-galactosidase assay
OCT-embedded sections of mammary tumours were proc-
essed and stained with X-gal as described previously [6].
qRT-PCR
Total RNA was extracted from flash frozen mammary
tumours and lung lesions using a Qiagen AllPrep DNA/
RNA Mini Kit (Qiagen Inc., Toronto, ON, Canada;
#80204). cDNA was prepared by reverse transcribing the
isolated RNA using M-Mulv Reverse Transcriptase
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RNase inhibitor (#M0314S) (all purchased from New
England Biolabs). Real-time quantitative PCR was
performed on the cDNA using LightCycler 480 SYBR
Green I Master (Roche, Missisauga, ON, Canada;
#04707516001) and run on a Roche LightCycler 480
instrument. Primers used for PyV mT were as follows:
forward - 5’CCCGATGACAGCATATCCCC-3’; reverse -
5’CTTGTTCCCCCGGTAGGATC-3’. PyV mT transcript
levels were normalized to GAPDH transcript levels.
DNA sequencing
Total DNA was extracted from flash frozen mammary
tumours and lung lesions using a Qiagen AllPrep
DNA/RNA Mini Kit (#80204). Genomic DNA was ana-
lysed by Sanger sequencing (Applied Biosystems 3730
DNA Analyser; Life Technologies Inc., Burlington, ON,
Canada) using the following primers to detect SNPs in


































Reverse - CTACTCAGAGAGGGGGCTGAPhospho-RTK array
The Proteome Profiler Mouse Phospho-receptor tyrosine
kinase (RTK) Array Kit from R&D Systems/Cedarlane
Corp., Burlington, ON, Canada (#ARY014) was used ac-
cording to the manufacturer’s instructions. Flash frozen
mammary tissues were lysed as in [6] and 200 μg was
used for each array. Arrays spotted with RTK probes
were incubated with biotin-conjugated phospho-tyrosine
antibody (EMD Millipore #16-103, 1:1,000) followed by
fluorescently-conjugated streptavidin (Mandel Scientific,
Guelph, ON, Canada; #LIC-926-32230, 1:1,000) to allow for
visualization on the Odyssey Imaging System (LI-COR Bio-
sciences, Lincoln, NE, USA). Fluorescence intensities for
each probe were normalized to a PBS probe (negative
control).
Results
Induction of MIC transgene expression in the mammary
gland results in rapid tumour onset
Polyomavirus middle T antigen (PyV mT) and Cre recom-
binase cDNAs were sub-cloned into a pTE vector contain-
ing an internal ribosome entry sequence (IRES) to
produce a TetO-PyV MIC transgene (Additional file 1:
Figure S1). MIC virgin females were aged to one year
without issue and the transgene did not disrupt normal
breeding in either sex or nursing by females. MIC founder
lines were crossed to the MMTV-rtTA strain to drive
doxycycline-inducible transgene expression to the mam-
mary epithelium [9]. Tumour onset in the original consti-
tutive MMTV-PyV mT model occurs with relatively short
onset, with virgin females developing mammary masses
with a T50 of 40 days of age [3,6]. To evaluate whether this
was also the case for the MIC model, we induced cohorts
of rtTA/MIC, rtTA and MIC virgin female mice between
8 and 16 weeks of age with 2 mg/mL doxycycline which
has been previously shown to lead to robust expression of
the Tet-inducible transgene in an MMTV-rtTA back-
ground [9]. The minimum age of eight weeks for induc-
tion was chosen to ensure that the mammary epithelium
would be almost fully developed. Induced animals were
initially examined every other day by physical palpation
for mammary tumour formation, alongside un-induced
controls of the same genotypes. A single founder line in
which mammary tumours were detected was chosen for
further breeding to generate cohorts that would be more
extensively characterized.
Mammary gland masses were detected in rtTA/MIC
mice as early as four days post-induction, with 74.4%
(29/39) of the cohort developing multifocal tumours
within 16 days of induction (Figure 1A). The few ani-
mals that did not palpate within this short 16-day win-
dow of induction could be subdivided into two groups:
those that developed tumours between 17 and 365 days
post-induction (12.8%; 5/39) and those that remained
Bnormal hyperplasia MIN adenocarcinoma
rtTA/MIC (+Dox)rtTA/MIC (-Dox)
A
Figure 1 Induced rtTA/MIC animals develop mammary tumours with characteristic histopathological features of PyV mT-driven
mammary tumourigenesis. (A) Kaplan-Meier mammary tumour onset curve as measured by physical palpation. A total of 87.1% (34/39) of mice
developed multifocal mammary tumours with a T50 of 7 days and an average of 22.0 ± 7.1 days post-induction with doxycycline. Control animals
(induced rtTA or MIC; un-induced rtTA/MIC) were monitored for at least one year. (B) Representative H&E-stained sections of normal ductal
structures in a mammary gland from a control animal (an un-induced rtTA/MIC) followed by typical stages of PyV mT mammary tumour
progression (hyperplasia, mammary intraepithelial neoplasia (MIN), and adenocarcinoma) in mammary glands and tumours from rtTA/MIC mice
following doxycycline induction. (Scale bar: 100 μm).
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Considering the entire rtTA/MIC induction cohort, the
average tumour onset was 22.0 ± 7.1 days post-
induction while the T50 was 7 days of induction, reflect-
ing the very rapid and complete induction observed in
the majority of animals. Precise regulation of the MIC
transgene was evident based on the concurrent observa-
tions that rtTA/MIC mice developed mammary tumours
exclusively and that all control animals (both induced
and un-induced) remained tumour-free after one year
post-induction.
Tumour growth in rtTA/MIC mice progressed dif-
ferently from what has been observed in the MMTV-
PyV mT model. In the latter, tumours develop as
focal masses in each gland that are easily measurable.
At defined time-points, histological analysis of the in-
guinal mammary glands from MMTV-PyV mT mice
shows a gradient of transformation, with the older
and more advanced lesions proximal to the nipple,
and newer lesions at earlier stages of tumourigenesis
towards the terminal end buds of the epithelial net-
work [13]. While distinct masses are initially palpable
in an induced rtTA/MIC mouse, the entire gland
promptly thickens within days, making it difficult to
perform calliper measurements at this stage. Animals
sacrificed at onset (approximately four days post-induction) or two weeks post-induction harboured in-
guinal mammary glands filled with early lesions (data
not shown; Additional file 2: Figure S2). This differ-
ence between the two models could be explained by
the fact that constitutive PyV mT-mediated trans-
formation occurs during puberty as the ductal epithe-
lial network progressively penetrates the fat pad,
while in the MIC model transformation was initiated
in an almost mature gland.
All tumour-bearing rtTA/MIC females were sacri-
ficed at a total tumour volume of approximately six
cubic centimetres (denoted as “end-stage”). Histo-
logical analysis of mammary glands and tumours from
these animals revealed the presence of all previously
characterized stages of PyV mT tumourigenesis, ran-
ging from hyperplasia, to MIN/adenoma, and finally
to early and late carcinoma (Figure 1B; Additional
file 3: Figure S3B). Adjacent mammary gland whole
mounts from tumour-bearing mice were also fully
transformed (Additional file 3: Figure S3A). Mammary
gland sections and whole mounts from age-matched
control animals were normal (Figure 1B; Additional
file 4: Figure S4). It appeared that our novel inducible
PyV mT strain was closely recapitulating the histo-
logical stepwise tumour progression documented in
the MMTV-PyV mT model.
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oncogene and a functional Cre recombinase
Having established that mammary tumours were indeed
inducible in the rtTA/MIC system, our next step was to
verify expression of the MIC transgene by immunohisto-
chemistry. PyV mT and Cre recombinase antibodies
stained the membrane and nuclei, respectively, of cells
in rtTA/MIC lesions in a mosaic pattern (Figure 2A).
Notably, normal ductal epithelium in both age-matched
controls and wildtype animals did not stain positively for
PyV mT or Cre recombinase.
To confirm MIC transgene expression by immunoblot,














Figure 2 PyV mT and Cre recombinase are expressed at all stages of
(middle row) and Cre recombinase (bottom row) in ductal structures at the
contrasted by normal mammary gland histology from control (an un-induc
sections are shown for comparison (top row). (Scale bar: 100 μm). (B) Imm
(mg), mammary tumours (tum) and adjacent mammary glands (amg) from
palpation after 16 days of induction) as indicated using antibodies directed
and α-tubulin (loading control). Controls include (from left to right) mamm
mouse and one induced rtTA mouse. Positive controls for PyV mT and Cre
(PyV mT) and MMTV-NIC (NIC) animals, respectively; arrowheads indicate spand tumours from rtTA/MIC mice sacrificed at palpa-
tion or at end-stage tumour burden (“late onset” refers
to palpation after 16 days of induction). These lysates
were positive for PyV mT expression; Cre recombinase
was also detected in rtTA/MIC tumours, although it was
lowly expressed in mammary gland lysates which likely
have relatively less epithelial content as indicated by E-
cadherin levels (Figure 2B). Induced and un-induced
control mammary glands did not express PyV mT or
Cre recombinase protein.
In order to use this model for Cre recombinase/LOXP-
mediated excision of genes, we needed to confirm that








tumourigenesis. (A) Immunohistochemical detection of PyV mT
indicated stages of mammary tumour progression in rtTA/MIC mice,
ed rtTA/MIC) and wildtype mice. The corresponding H&E-stained
unoblot analysis of protein lysates from rtTA/MIC mammary glands
animals sacrificed at palpation or at end-stage (“late onset” refers to
to E-cadherin (epithelial content control), PyV mT, Cre recombinase
ary glands from two un-induced rtTA/MIC mice, one induced MIC
recombinase expression were mammary tumours from MMTV-PyV mT









Figure 3 Cre recombinase expression and activity are uniform in the epithelium of rtTA/MIC mammary tumours. X-gal staining (blue) of
mammary tumour sections from rtTA/MIC animals carrying the Cre recombinase-activated β-galactosidase reporter transgene (GTRosa). Negative
controls include MMTV-PyV mT mammary tumours with either GTRosa (PyV mT/GTRosa) or MMTV-Cre recombinase transgenes (PyV mT/Cre
recombinase). An MMTV-PyV mT mammary tumour with both transgenes (PyV mT/Cre recombinase/GTRosa) was used as a positive control.
Samples were counterstained with nuclear fast red (pink). (Scale bar: 500 μm).
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Rosa26-β-galactosidase reporter strain (“GTRosa”) in
which the lacZ gene is downstream of a LOXP-flanked
STOP cassette [12]. The presence of Cre recombinase al-
lows for expression of the β-galactosidase enzyme from
the lacZ transgene, which can cleave the compound X-gal
into an insoluble blue-coloured product. The mammary
epithelium of rtTA/MIC/GTRosa tumour sections
turned blue upon staining with X-gal, indicating that
Cre recombinase had been expressed and active in
these cells (Figure 3). This outcome is comparable to
an MMTV-PyV mT/MMTV-Cre recombinase/GTRosa
mammary tumour in which there are no conditional al-
leles present. Collectively, these results demonstrate
that the rtTA/MIC mouse model can be used to study
Cre recombinase-dependent genetic alterations in con-
junction with PyV mT oncogenic activation.
The rapid induction of rtTA/MIC lesions is associated with
metastatic dissemination of tumour cells to the lung
One of the most useful features of the original constitu-
tive PyV mT model is the ability of the mammary tu-
mours to effectively metastasize to the lungs, an organ
that is a common site of distal lesions in the human dis-
ease. To determine if rtTA/MIC mammary tumours
were capable of forming pulmonary metastases, we ex-
amined sections of the lung lobes from animals that had
reached similar end-stage tumour burdens. All tumour-
bearing mice presented with lung metastases, albeit to
varying degrees, with some lungs harbouring only a few
small lesions while others were made up almost entirely
of secondary tumour tissue (Figure 4A, B). These lung
lesions stained positively for PyV mT, confirming that
they derived from the primary rtTA/MIC mammary
tumour (Figure 4C). Interestingly, there was no correl-
ation between the extent of metastasis and tumourburden, extending the idea that PyV mT tumours are
heterogeneous in their transforming capabilities and
may thus also be in terms of malignancy (data not
shown; [13]). Taken together, these observations demon-
strate that this inducible MIC model reproduces many
of the pathological features of the original MMTV-PyV
mT strain.
De-induction of the MIC transgene results in immediate
tumour regression and eventual recurrence of
doxycycline-independent masses
Another important feature of inducible systems is the
capacity to “turn off” the oncogene by withdrawal of the
inducing agent; one can then evaluate whether tumours
regress and if they have the potential to recur in the ab-
sence of transgene expression. To test this in our model,
doxycycline treatment was discontinued for a cohort of
rtTA/MIC mice bearing end-stage mammary tumours.
Upon de-induction of PyV mT expression the tumours
began to shrink rapidly (Figure 5A). By 10 weeks post-
de-induction, most of the tumours had regressed to
palpable masses that were no longer measurable. Inter-
estingly, all of the de-induced rtTA/MIC mice eventually
developed recurrent masses (15 to 50 weeks post-de-
induction) and were sacrificed at burden endpoint. The
number of measurable recurrent tumours arising was
significantly less than the number of measurable masses
the animal had prior to de-induction (Figure 5B). This
suggests that the emergence of more focal, doxycycline-
independent tumours in post-regression mice is a spon-
taneous event, in contrast to the consistent and complete
penetrance of multifocal, doxycycline-dependent tumours
driven by the inducible MIC transgene to all mammary
glands of a given animal. Doxycycline-independent tu-
mours arose only in rtTA/MIC mice and not in control













Figure 4 rtTA/MIC end-stage mammary tumours exhibit a high capacity for metastatic dissemination to the lungs. (A) Quantification of
the number of metastatic lung lesions (left axis) and the percentage of lung tissue occupied by metastases (right axis) in rtTA/MIC animals at
end-stage tumour burden. Bars represent the average value for each parameter. (B) H&E-stained whole lung sections representative of low,
medium and high levels of metastasis. (C) Representative lung lesion from a tumour-bearing rtTA/MIC animal stained with H&E (top row) and PyV
mT (bottom row). An MMTV-NIC (NIC) lung lesion is shown as a negative control for PyV mT staining (Scale bar: 200 μm).
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regression tumours and completely regressed mammary
glands revealed relatively normal ductal structures sur-
rounded by extensive stromal deposition and occasionally
abnormal adipose tissue, which may explain why these
glands remained palpable so long after de-induction (data
not shown).
The morphology of the recurrent masses exhibited
striking intra- and intertumoural heterogeneity, with
individual tumours differing among animals and among
tumours from the same mouse (Figure 6A; Additional
file 5: Figure S5A). Some histopathologies resembled
pre-regression adenocarcinoma while others were more
divergent, such as epithelial-mesenchymal-transition (EMT)-
like and striated/punctate morphologies. All mice with
recurrent tumours had evidence of lung metastases at
sacrifice, varying in number, size and stage (data not shown).
A single animal sacrificed prior to recurrent tumour devel-
opment did not present with any metastases which suggests
that, at least in this individual case, MIC-induced lung le-
sions may regress in parallel with the primary tumour upon
doxycycline withdrawal.To determine if the recurrent tumours were no longer
dependent on the PyV mT oncogene, we subjected ly-
sates from the five tumours shown in Figure 6A to im-
munoblot analysis (Figure 6B). Two samples clearly
showed detectable bands at the expected size for PyV
mT (2376 R1 and 3027 L4), while weaker signals were
observed in two other samples (2380 L1 and 2692); one
sample appeared to be completely negative for PyV mT
expression (2379). To achieve a more quantitative as-
sessment of PyV mT levels, qRT-PCR was carried out
on these and other recurrent tumours as well as corre-
sponding metastatic lung lesions from two animals. We
found that PyV mT transcript levels in the recurrent tu-
mours reflected the protein levels obtained by immuno-
blotting (Additional file 5: Figure S5B). For the most
part, re-expression of the PyV mT transgene correlated
with the incidence of adenocarcinoma in the tumour’s
corresponding histological section. The lack of complete
correlation can be explained by the fact that we must
use different pieces of a histologically heterogeneous
tumour for different analyses. Interestingly, a PyV mT
transcript was detected in a metastatic lung lesion in
Figure 5 Doxycycline withdrawal in rtTA/MIC tumours leads to rapid regression and eventual spontaneous recurrence of masses. (A)
Total mammary tumour burden measured over time in rtTA/MIC mice prior to and following doxycycline withdrawal (indicated by the dotted
line at time 0). Tumour-bearing mice were de-induced upon reaching burden endpoint. Each line represents an individual animal labeled by its
ID number. (B) Quantification of the number of measurable masses detected pre-regression (pre), at the point of maximum regression (mid) and
at sacrifice (recurrent). Bars represent the average value at each time-point. **P <0.01.
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(2376; Additional file 5: Figure S5B); PyV mT protein ex-
pression in the lung lesions was confirmed by immuno-
histochemistry (data not shown). On the other hand, in
an animal with a PyV mT-expressing recurrent tumour
(2380 L1) and a -non-expressing recurrent tumour
(2380 L3), PyV mT transcript was undetectable in a
metastatic lung lesion. This may reflect the presence of
separate recurrent lesions that either re-expressed the
transgene or arose in the absence of PyV mT transcript.
It may additionally indicate the capability of non-
PyV mT-expressing, recurrent mammary lesions to
metastasize to the lungs, or the PyV mT-independent re-
currence of an originally doxycycline-dependent lung
metastasis in situ. We should note that the lower tran-
script levels of PyV mT transgene in the rtTA/MIC tu-
mours relative to that of the MMTV-PyV mT tumour
are likely due to the different strengths of the promoters
driving the transcription of the oncogene (TetON versus
MMTV). This does not impact on overexpression of
PyV mT protein in the inducible system, as evidenced
by the strong levels detected by immunoblot (Figure 2B)
and ultimately the fact that transformation occurs rap-
idly in the model.It appeared that while some recurrent tumours arose by
re-expressing the PyV mT transgene, others did so by al-
ternative mechanisms. In an attempt to identify these po-
tential mediators of recurrence, we used an antibody array
to analyse phospho-RTK levels in primary and recurrent
tumour lysates and focused on candidates with relatively
high fluorescence intensities, specifically epidermal growth
factor receptor (EGFR), ErbB2 and platelet-derived growth
factor receptor (PDGFR) β (Additional file 6: Figure S6A).
While not all candidates validated by immunoblotting, we
did observe phosphorylation of both ErbB2 and PDGFRβ
in at least some of the recurrent tumours, suggesting that
RTK signalling was actively occurring (Additional file 6:
Figure S6B). ErbB2 is known to be up-regulated during
mammary tumour progression in the MMTV-PyV mT
model [4]. While we observed relatively low expression of
ErbB2 in our samples as compared to an MMTV-NIC
control lysate, the strong levels of phosphorylated ErbB2
in the doxycycline-independent rtTA/MIC recurrences
may represent an avenue of recapitulating the signalling
associated with PyV mT tumourigenesis in the absence of
transgene re-expression. This may be the case for 2379,
which also showed overexpression of c-Myc protein; inter-















































Figure 6 Recurrent masses from de-induced rtTA/MIC mice have variable histopathologies and some exhibit re-expression of PyV mT.
(A) H&E-stained recurrent mammary tumours arising in rtTA/MIC mice post-doxycycline withdrawal. The mouse ID number (followed by the
tumour location in the case of multiple recurrences, for example, “R1”) and histopathology of the tumour are indicated for each image. A
pre-regression rtTA/MIC doxycycline-dependent mammary tumour exhibiting typical end-stage adenocarcinoma is shown for comparison. (Scale
bar: 100 μm). (B) Immunoblot analysis of protein lysates from rtTA/MIC mammary tumours prior to and following doxycycline withdrawal using
antibodies directed to E-cadherin (epithelial content control), PyV mT, Cre recombinase and Hsp90 (loading control); the arrowhead indicates the
specific band for PyV mT protein. Resected mammary tumours were used for pre- and mid-regression time-points (pre- and mid-, respectively),
while recurrent masses were harvested from mice sacrificed at clinical endpoint. The mouse ID numbers of the recurrent tumour lysates are
indicated and correspond to the images labeled in (A). The incidence of adenocarcinoma in the corresponding histological section for each
sample is indicated by a “+” symbol.
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the doxycycline-dependent oncogene [14].
To further analyze the potential occurrence of cooperat-
ing oncogenic events during the process of doxycycline-
independent recurrence of rtTA/MIC mammary tumours,
we sequenced regions of the three Ras genes (Hras, Kras1
and Nras) and of Trp53 that are orthologous to those fre-
quently mutated in human cancers. Notably, mutations inthese genes have been previously identified as potential
driving events in the recurrence of other doxycycline-
driven transgenic mouse tumour models [15,16]. No mu-
tations were found in any of the genes examined in
doxycycline-dependent rtTA/MIC mammary tumours
(data not shown). In recurrent mammary tumours, we
found no mutations in exons 2 and 3 (containing codons
12 and 61) of either of the Ras genes but did identify an
Rao et al. Breast Cancer Research 2014, 16:R11 Page 11 of 14
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(R245C) in one recurrent mammary tumour (2380 L1;
data not shown). The affected residue corresponds to
R248 of human TP53, which is frequently mutated in
human cancer. This result suggests that mutations in
known tumour suppressor genes can occur in recurrent
rtTA/MIC mammary tumours. However, at least in the
case of Trp53, they may be relatively infrequent (1/10
samples examined). A more comprehensive mutational
analysis (for example, using exome sequencing) of
doxycycline-dependent and recurrent rtTA/MIC mam-
mary tumours could be undertaken in the future to
provide additional information on cooperating genetic
events during tumour recurrence.
Collectively, these data illustrate that, while we can
demonstrate rapid tumour regression in rtTA/MIC ani-
mals by withdrawal of doxycycline, the emergence of
doxycycline-independent tumours ultimately transpires.
This can be attributed in at least some cases to the re-
activation of the PyV mT transgene and corresponds
with an adenocarcinoma phenotype. In other cases,
tumour recurrence may be associated with activation of
RTK signalling and/or cooperating oncogenic mutations,
such as the observed mutation in Trp53. These events
may correlate with a different spectrum of tumour his-
topathologies, since the occurrence of the R245C muta-
tion in 2380 L1 correlates with the appearance of an
EMT-like morphology in addition to adenocarcinoma
(Figure 6A). This is in keeping with the established
tendency of Trp53 mutations to induce tumours with
EMT-type histopathological features in transgenic mouse
models [17].
Discussion
The development of inducible transgene systems for
in vivo studies has made it possible to more accurately
model human diseases. The ability to control transgene
expression in mice allows the researcher to initiate
tissue-specific changes at relevant time-points and, in
the case of oncogenic transgenes such as PyV mT,
mimic disease initiation (induction) and treatment (de-
induction). The TetO-PyV mT-IRES-Cre recombinase
(MIC) strain generated in our laboratory not only uti-
lizes inducible expression of the PyV mT oncoprotein,
but incorporates Cre recombinase-mediated genetic
changes as well, due to the bi-cistronic linking of these
transgenes. In this study, we have chosen a mammary
epithelial-specific rtTA (MMTV-rtTA) to characterize a
new model of mammary tumourigenesis driven by the
MIC transgene.
Induction of rtTA/MIC mice with doxycycline led to
the rapid onset of invasive mammary tumours in the
majority of animals. MIC-expressing lesions developed
in a stepwise fashion that resembled the progressionobserved in the constitutive MMTV-driven model of
PyV mT tumourigenesis (MMTV-PyV mT). Notably,
earlier lesions displayed more uniform staining of PyV
mT and Cre recombinase protein and at a higher inten-
sity than carcinoma stages, suggesting a potential damp-
ening of transgene expression once the tumour has
progressed (Figure 2A). There may be a reduced require-
ment for strong PyV mT levels in an advanced lesion
due to the presence of other genetic aberrations. Despite
a rapid tumour onset, it may be possible for cooperating
genetic or epigenetic events to occur in this short time
period; in fact, constitutive expression of PyV mT was
shown to be insufficient for transformation without add-
itional changes in endogenous genes [13]. This hypoth-
esis may be extended to the expression of Cre
recombinase. The homogenous staining of rtTA/MIC
mammary tumours obtained in the X-gal assay contrasts
with the heterogeneous Cre recombinase expression de-
termined by immunohistochemistry, which may simply
be due to inherent differences between the two analyses
(Figure 2A; Figure 3). We suspect that all of the mam-
mary epithelial cells in these animals expressed Cre re-
combinase at some point at least once given that 100%
of the tumour epithelium is positive for the β-
galactosidase reporter; however, as Cre recombinase is
only required for the initial recombination event, its ex-
pression may have been turned off during tumour pro-
gression. The functionality and tight regulation of Cre
recombinase by doxycycline in this model was ultimately
validated by our preliminary findings that conditional
loss of the p110α isoform of phosphatidyl inositol 3’ kin-
ase - a critical mediator of PyV mT signaling in vitro
and hypothetically essential for tumourigenesis in vivo -
is achievable in the rtTA/MIC model, leading to abroga-
tion of tumour formation in animals induced for at least
200 days [18] (unpublished observations; Rao T, Muller
WJ, Zhao JJ).
One important difference between the inducible PyV
mT model and the conventional MMTV-PyV mT model
is that tumour development in our inducible PyV mT
model was not 100% penetrant. A proportion of the ani-
mals in our cohort either developed masses much later
than 16 weeks post-induction or had no palpable masses
prior to one year post-induction (Figure 1A). Despite
the longer latency, the tumours from the late onset
group resembled early onset tumours in terms of pro-
gression, metastatic capacity and MIC transgene expres-
sion (data not shown; Figure 2B). The delayed onset in
some rtTA/MIC mice contrasts with the complete pene-
trance observed in both the MMTV-PyV mT strain and
the previously published inducible PyV mT strain
(TetO-PyV mT-IRES-Luciferase) [3,10]. An initial ex-
planation would be that the discrepancy is due to differ-
ences in the number and/or location of the transgene
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pear to be more permissible than others. Another pos-
sible explanation is that the rtTA is non-responsive
in certain transgene carriers. However, this is not likely
the case, as demonstrated by the robust induction of
hyperplastic lesions in mammary gland whole mounts
from 100% (19/19) of animals following two weeks of
doxycycline administration (Additional file 2: Figure
S2A). Analysis of mammary gland sections at this time-
point revealed that the ducts were almost exclusively
abnormal (either hyperplastic or filled), in contrast to
only normal ducts in a control animal (Additional file 2:
Figure S2B, C). These data argue that the observed in-
complete tumour penetrance is not due to technical
issues with the inducible MIC system but rather reflects
the natural history of tumour development and progres-
sion in this model. An additional theory for the differ-
ence in tumour penetrance deals with the fact that PyV
mT and Cre recombinase are expressed during adult-
hood and may be subject to immune rejection, in con-
trast to the pre-pubescent onset of PyV mT expression
in the conventional MMTV-PyV mT model. We may
have some evidence to support this hypothesis: unpub-
lished experiments in our laboratory have found that
MMTV-NIC mammary tumour cells do not grow in
immune-competent mice, while they readily propagate
in immune-compromised hosts (for example, NCr,
SCIDbeige) or in a tolerant environment, such as the
MMTV-Cre recombinase strain. Moreover, MMTV-
NDL mammary tumour cells, which lack Cre recombin-
ase but express the same ErbB2/Neu oncogene used in
the MMTV-NIC model, are tolerated in an FVB/N back-
ground (unpublished observations; Muller WJ). Future
studies investigating the sustainability of rtTA/MIC
mammary epithelial cells in immune-deficient mice
should allow this issue to be addressed.
The inducibility of the MIC transgene and mammary
tumour progression in our model was found to be
reversible upon withdrawal of doxycycline; however,
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cells (by X-gal assay)
0%
for
Percentage of tumour-bearing mice with lung metastases 93in de-induced animals (Figure 5). It is possible that
the accruement of additional genetic lesions during
doxycycline-dependent tumour progression allowed the
regressed mammary glands to reinitiate tumourigenesis.
Unlike typical end-stage rtTA/MIC mammary tumours,
the recurrent masses were often focal and the remarkable
array of histopathologies documented was unexpected,
particularly considering the homogeneous nature of the
initial doxycycline-dependent tumours which all presented
as adenocarcinoma at end-stage (Figure 6A; Additional
file 5: Figure S5A). As revealed by immunoblotting and
qRT-PCR analyses of recurrent tumour lysates, reactiva-
tion of signalling may be attributable to re-expression of
the MIC transgene in some cases (Figure 6B; Additional
file 5: Figure S5B). Indeed, reactivation of inducible trans-
genes as a consequence of mutations in the rtTA has been
reported previously and may present a possible explan-
ation for a subset of our recurrent tumours [19]. From a
clinical standpoint, the fact that tumours can evolve in the
absence of PyV mT reactivation recapitulates the well-
established problem of therapeutic resistance in breast
cancer. The PyV mT oncogene is widely regarded as an
RTK mimic and so the recurrence experiment could be
thought of as another way of modelling recurrence of
RTK-driven breast cancer upon chronic administration of
an RTK inhibitor. Indeed, several of the recurrent tumours
(including a non-PyV mT-expressing sample) showed ex-
pression and/or activation of known proto-oncogenes
(Additional file 6: Figure S6), while one tumour also
carried an oncogenic mutation in the Trp53 tumour sup-
pressor. In the latter case, we cannot exclude the possibil-
ity that the primary tumours that gave rise to these
recurrences included tumour cell populations that had
already undergone this genetic event. However, its absence
in the panel of doxycycline-dependent samples we ana-
lysed suggests that it may also occur de novo during the
process of tumour regression and recurrence. In sum-
mary, our rtTA/MIC model of de-induction appears to
be a valuable system for investigating clinical treatment
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We have demonstrated that our novel MIC mouse strain
in conjunction with the MMTV-rtTA is a suitable model
of PyV mT mammary tumourigenesis with the added
benefit of temporal regulation. Our rtTA/MIC mice
can be induced to develop metastatic tumours in a clas-
sical stepwise fashion, closely recapitulating the human
disease. A brief comparison of our new model with the
original, constitutive MMTV-PyV mT strain emphasizes
the greater experimental practicality of the former
(Table 1). In addition to the inherent improvements to
the mouse model design (that is, inducibility of the
oncogene combined with coupling to Cre recombinase),
tumour initiation begins just days after induction of
the MIC transgene with complete penetrance to all
mammary glands. Importantly, the rtTA/MIC model
maintains key desirable traits of its predecessor in terms
of tumour progression, in particular, the invasive, meta-
static nature of PyV mT mammary tumour cells to distal
sites such as the lungs. Perhaps the most useful feature
of the MIC strain is that it can be used to study the ef-
fect of Cre recombinase-dependent genetic alterations
on PyV mT-mediated transformation in any tissue with
the appropriate rtTA, making this an important clinical
tool for studying many types of cancer in the mouse.Additional files
Additional file 1: Figure S1. Figure illustrating doxycycline-inducible
expression of PyV mT and Cre recombinase in the mammary epithelium
of rtTA/MIC mice.
Additional file 2: Figure S2. Figure showing mammary glands from
rtTA/MIC mice.
Additional file 3: Figure S3. Figure showing adjacent mammary
glands from end-stage tumour-bearing rtTA/MIC mice.
Additional file 4: Figure S4. Figure showing mammary glands from
control animals (both induced and un-induced).
Additional file 5: Figure S5. Figure showing multiple histopathologies
from recurrent tumours and expression of PyV mT transcript.
Additional file 6: Figure S6. Figure showing RTK signalling in
doxycycline-independent masses in rtTA/MIC mice.Abbreviations
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